Dirk Schadendorf, MD | Authors

Articles

Combining Targeted Therapy With Checkpoint Blockade for the Treatment of Melanoma

August 31, 2017

Dirk Schadendorf, MD, professor, director, and chair of the clinic for dermatology at the University Hospital Essen in Germany, discusses the combination of targeted therapy and checkpoint blockade for the treatment of melanoma.

Association Between PD-L1/CD8 Expression and Outcomes in Melanoma Patients Who Received Dabrafenib/Trametinib

July 19, 2017

Dirk Schadendorf, MD, professor, director, and chair of the clinic for dermatology at the University Hospital Essen in Germany, discusses the association between PD-L1 and CD8 expression and outcomes in patients with BRAF V600E/K-mutant metastatic melanoma who received dabrafenib (Tafinlar) plus trametinib (Mekinist) in the randomized phase III COMBI-v study.